Press Room

Event

RDD Europe 2015

Start
Tuesday, May 05, 2015 - 00:00
End
Friday, May 08, 2015 - 00:00
Location: Nice, France
Booth Number: Table nr. 32

RDD Europe 2015 will be held from Tuesday 5th May until Friday 8th May 2015 at the Palais des Congres d'Antibes, Nice, France. Hovione will be present with a table (nr. 32), a presentation, a workshop and a set of posters.

Contact us if you would like to schedule a meeting or to find more about the Hovione posters at RDD.

contact us button | Hovione
http://go.hovione.com/l/47122/2015-04-27/67pjt

 

HOVIONE'S PRESENTATION

Optimized Composite Particles for API-independent Formulations with Enhanced Performance

Speaker: Eunice Costa, PhD (Scientist, Drug Product Development)

Date: Friday, May 5, 2015

Time: 8:30 AM

HOVIONE'S WORKSHOP

Trends in Inhalation Drug Development: Particle Engineering and Formulation Strategies

Speakers: Eunice Costa, PhD (Scientist, Drug Product Development)

                  Filipe Neves, PhD (Senior Scientist, Group Leader, Drug Product Development)

Date: Wednesday, May 6, 2015 

Time: tbd - afternoon from 2:00 to 6:00 PM

  • Introduction: This workshop addresses trends in particle engineering (PE) technologies, and formulation strategies to overcome problems during the development of inhalation drugs. Participants will gain insight into innovative approaches via comprehensive and diverse case studies chosen to illustrate the complexity of manufacturing processes. 

     
  • Workshop Content: Participants will learn the fundamentals of inhalation delivery, together with an overview of market trends and basic concepts associated with metered dose inhalation (MDI) and dry powder inhalation (DPI); for the latter platform, carrier based and composite particles based approaches will be emphasized. The impact of different particle engineering technologies on the final performance of both MDI and DPI (carrier based) products will be discussed. Case studies will link API properties (measured by cutting edge techniques) and formulation strategy, with the overall success of a given delivery platform. Lastly, DPI formulation based on spray dried composite particle approaches will be explored using case studies covering formulation development and process scale-up.

     
  • Outcome for Participants: The participants will gain insight into several innovative approaches, including a number of comprehensive and diverse case studies, which will illustrate the complex relationships linking inhaler design to particle engineering and formulation strategies.

     

POSTERS

Impact of the Size-Reduction Technology on the Performance of Suspension Pressurized Metered Dosed Inhalers: Benchmarking with Dry Powder Inhalers

Eunice Costa

Performance Optimization in Early DPI Development: Enabling High Dosage Drug Delivery to the Lungs Through Orifice-Based Aerosolization

João Fernandes

Benchmarking Gravimetric FSI vs ACI: Can We Expedite Aerodynamic Performance Evaluation for Composite Powders?

Isabel Lopes

Aerodynamic Performance of DPIs: Predicting the Impact of Carrier-Based Formulation Parameters

Filipa Maia

API Influence & Stability Assessment of Spray Dried Composite Particles

Cláudia Moura

Optimizing Trade-Offs Between Product Performance and Process Efficiency via Powder Rheology

Maria Palha

 

 

Also in the Press Room

See All

Every year, the largest bank in Portugal, Caixa Geral de Depósitos recognizes some of Portugal’s brightest young minds through the Caixa +Mundo Awards, providing nearly €800,000 in scholarships to students as they pursue higher education. In this year´s edition, Caixa named the award bestowed upon students pursuing science for Diane Villax. This prestigious honor places Diane Villax among the award’s namesakes – a distinguished group of prominent personalities who have made notable contributions to Portugal´s socio-economic, cultural, political and scientific development over the last 50 years, such as António Ramalho Eanes, Mário Soares, José Saramago, Sophia de Mello Breyner, Leonor Beleza, Elvira Fortunato, Rui Nabeiro, Américo Amorim, and José Manuel de Mello. Diane Villax will also honor the seven scientific award winners by personally meeting with each of them, and following their journeys as future innovators and leaders. But this honor is about far more than one individual. It is a celebration of an entire organization and the people behind it. For 67 years, generations of dedicated teams have worked together with passion, purpose, and excellence to manufacture life-saving medicines and advance science that has a real impact on people. This recognition belongs to all of us.    

News

Prestigious Caixa +Mundo Award named in honor of Diane Villax

May 14, 2026

CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing services. The companies partnered in 2023 with plans for development of two capsule-based devices for intranasal delivery: the single-use device and a multidose device. Read the full article at OINDPnews.com      

Press Clipping
OINDP - Orally inhaled and nasal drug products news, May 11, 2026

Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

May 11, 2026

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping
Contract Pharma, 7 May 2026

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026

Also in Events

See All